BACKGROUND: An antimicrobial stewardship program was fully implemented at the University of Maryland Medical Center in July 2001 (beginning of fiscal year [FY] 2002). Essential to the program was an antimicrobial monitoring team (AMT) consisting of an infectious diseases-trained clinical pharmacist and a part-time infectious diseases physician that provided real-time monitoring of antimicrobial orders and active intervention and education when necessary. The program continued for 7 years and was terminated in order to use the resources to increase infectious diseases consults throughout the medical center as an alternative mode of stewardship. DESIGN: A descriptive cost analysis before, during, and after the program. PATIENTS/ SETTING: A large tertiary care teaching medical center. METHODS: Monitoring the utilization (dispensing) costs of the antimicrobial agents quarterly for each FY. RESULTS: The utilization costs decreased from $44,181 per 1,000 patient-days at baseline prior to the full implementation of the program (FY 2001) to $23,933 (a 45.8% decrease) by the end of the program (FY 2008). There was a reduction of approximately $3 million within the first 3 years, much of which was the result of a decrease in the use of antifungal agents in the cancer center. After the program was discontinued at the end of FY 2008, antimicrobial costs increased from $23,933 to $31,653 per 1,000 patient-days, a 32.3% increase within 2 years that is equivalent to a $2 million increase for the medical center, mostly in the antibacterial category. CONCLUSIONS: The antimicrobial stewardship program, using an antimicrobial monitoring team, was extremely cost effective over this 7-year period.
BACKGROUND: An antimicrobial stewardship program was fully implemented at the University of Maryland Medical Center in July 2001 (beginning of fiscal year [FY] 2002). Essential to the program was an antimicrobial monitoring team (AMT) consisting of an infectious diseases-trained clinical pharmacist and a part-time infectious diseases physician that provided real-time monitoring of antimicrobial orders and active intervention and education when necessary. The program continued for 7 years and was terminated in order to use the resources to increase infectious diseases consults throughout the medical center as an alternative mode of stewardship. DESIGN: A descriptive cost analysis before, during, and after the program. PATIENTS/ SETTING: A large tertiary care teaching medical center. METHODS: Monitoring the utilization (dispensing) costs of the antimicrobial agents quarterly for each FY. RESULTS: The utilization costs decreased from $44,181 per 1,000 patient-days at baseline prior to the full implementation of the program (FY 2001) to $23,933 (a 45.8% decrease) by the end of the program (FY 2008). There was a reduction of approximately $3 million within the first 3 years, much of which was the result of a decrease in the use of antifungal agents in the cancer center. After the program was discontinued at the end of FY 2008, antimicrobial costs increased from $23,933 to $31,653 per 1,000 patient-days, a 32.3% increase within 2 years that is equivalent to a $2 million increase for the medical center, mostly in the antibacterial category. CONCLUSIONS: The antimicrobial stewardship program, using an antimicrobial monitoring team, was extremely cost effective over this 7-year period.
Authors: Johannes P Borde; Sarah Nussbaum; Stefanie Hauser; Philip Hehn; Johannes Hübner; Gabriela Sitaru; Sebastian Köller; Bruno Schweigert; Katja deWith; Winfried V Kern; Klaus Kaier Journal: Infection Date: 2015-10-16 Impact factor: 3.553
Authors: R S Evans; J A Olson; E Stenehjem; W R Buckel; E A Thorell; S Howe; X Wu; P S Jones; J F Lloyd Journal: Appl Clin Inform Date: 2015-03-03 Impact factor: 2.342
Authors: Rebekah W Moehring; Kevin C Hazen; Myra R Hawkins; Richard H Drew; Daniel J Sexton; Deverick J Anderson Journal: J Clin Microbiol Date: 2015-07-15 Impact factor: 5.948
Authors: Christopher J Graber; Makoto M Jones; Peter A Glassman; Charlene Weir; Jorie Butler; Kevin Nechodom; Chad L Kay; Amy E Furman; Thuong T Tran; Christopher Foltz; Lori A Pollack; Matthew H Samore; Matthew Bidwell Goetz Journal: Hosp Pharm Date: 2015-11-24